Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned an average rating of “Hold” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.17.

Several analysts have commented on HALO shares. Barclays PLC reiterated an “overweight” rating and set a $16.00 target price on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. Piper Jaffray Companies set a $20.00 target price on Halozyme Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Friday, August 25th. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Jefferies Group LLC reiterated an “underperform” rating and set a $7.00 target price (up from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/16/halozyme-therapeutics-inc-halo-given-consensus-recommendation-of-hold-by-analysts.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning lifted its position in Halozyme Therapeutics by 1.2% during the second quarter. Creative Planning now owns 114,667 shares of the biopharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 1,383 shares in the last quarter. American International Group Inc. lifted its position in Halozyme Therapeutics by 7.0% during the first quarter. American International Group Inc. now owns 67,109 shares of the biopharmaceutical company’s stock valued at $870,000 after purchasing an additional 4,407 shares in the last quarter. Chicago Equity Partners LLC lifted its position in Halozyme Therapeutics by 85.5% during the second quarter. Chicago Equity Partners LLC now owns 315,440 shares of the biopharmaceutical company’s stock valued at $4,044,000 after purchasing an additional 145,410 shares in the last quarter. BlackRock Inc. lifted its position in Halozyme Therapeutics by 7,292.8% during the first quarter. BlackRock Inc. now owns 11,062,842 shares of the biopharmaceutical company’s stock valued at $143,374,000 after purchasing an additional 10,913,199 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in Halozyme Therapeutics by 37.2% during the first quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 14,308 shares in the last quarter. Institutional investors own 85.06% of the company’s stock.

Shares of Halozyme Therapeutics (HALO) traded up 4.58% on Wednesday, hitting $18.27. The company had a trading volume of 568,292 shares. The stock’s market capitalization is $2.45 billion. Halozyme Therapeutics has a 52 week low of $8.18 and a 52 week high of $18.43. The firm’s 50 day moving average price is $15.58 and its 200-day moving average price is $13.72.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter in the prior year, the business posted ($0.21) earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Analysts forecast that Halozyme Therapeutics will post ($0.13) earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.